Multiple Myeloma: Fluciclovine PET/CT Imaging Study

We are investigating a new imaging method for multiple myeloma patients to see how it compares to standard imaging. This study aims to understand its effectiveness and safety in detecting the disease.

Efficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInjectionOncologyOtolaryngology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Axumin
Axumin is a medical imaging substance used during PET scans to help find prostate cancer that may have returned after treatment.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Fluciclovine (18f)
Fluciclovine (18F) is a radioactive imaging tracer used in PET scans to help detect recurrent prostate cancer.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Oslo University Hospital HF
The Intervention Centre
Oslo, Norway
Sponsor: Oslo University Hospital HF
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.